IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice

James S Wolffsohn; Monica Jong; Earl L Smith; Serge R Resnikoff; Jost B Jonas; Nicola S Logan; Ian Morgan; Padmaja Sankaridurg; Kyoko Ohno-Matsui

doi:10.1167/iovs.62.5.1

IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice

James S Wolffsohn, Monica Jong, Earl L Smith, Serge R Resnikoff, Jost B Jonas, Nicola S Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui

Optometry and Vision Science

Research output: Contribution to journal › Special issue › peer-review

13 Citations (Scopus)

49 Downloads (Pure)

Abstract

The International Myopia Institute's (IMI) mission is to advance research, education, and management of myopia to decrease future vision impairment and blindness associated with increasing myopia. Its approach is to bring together scientists, clinicians, policymakers, government members, and educators into the field of myopia to stimulate collaboration and sharing of knowledge. The latest reports are on pathologic myopia, the impact of myopia, risk factors for myopia, accommodation and binocular vision in myopia development and progression, and the prevention of myopia and its progression. Together with the digest updating the 2019 International Myopia Institute white papers using the research published in the last 18 months, these evidence-based consensus white papers help to clarify the imperative for myopia control and the role of environmental modification initiatives, informing an evidence-based clinical approach. This guidance includes who to treat and when to start or stop treatment, and the advantages and limitations of different management approaches.

Original language	English
Article number	1
Pages (from-to)	1-5
Number of pages	5
Journal	Investigative ophthalmology & visual science
Volume	62
Issue number	5
DOIs	https://doi.org/10.1167/iovs.62.5.1
Publication status	Published - 28 Apr 2021

Access to Document

10.1167/iovs.62.5.1Licence: CC BY-NC-ND

ArticleFinal published version, 215 KBLicence: CC BY-NC-ND

Cite this

@article{b438e87346e64534a51599d3d3107ba2,

title = "IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice",

abstract = "The International Myopia Institute's (IMI) mission is to advance research, education, and management of myopia to decrease future vision impairment and blindness associated with increasing myopia. Its approach is to bring together scientists, clinicians, policymakers, government members, and educators into the field of myopia to stimulate collaboration and sharing of knowledge. The latest reports are on pathologic myopia, the impact of myopia, risk factors for myopia, accommodation and binocular vision in myopia development and progression, and the prevention of myopia and its progression. Together with the digest updating the 2019 International Myopia Institute white papers using the research published in the last 18 months, these evidence-based consensus white papers help to clarify the imperative for myopia control and the role of environmental modification initiatives, informing an evidence-based clinical approach. This guidance includes who to treat and when to start or stop treatment, and the advantages and limitations of different management approaches.",

keywords = "Accommodation, Myopia, Myopia control, Pathologic myopia, Refractive error",

author = "Wolffsohn, {James S} and Monica Jong and Smith, {Earl L} and Resnikoff, {Serge R} and Jonas, {Jost B} and Logan, {Nicola S} and Ian Morgan and Padmaja Sankaridurg and Kyoko Ohno-Matsui",

note = "Funding Information: Supported by the International Myopia Institute. The publication costs of the International Myopia Institute reports were supported by donations from the Brien Holden Vision Institute, Carl Zeiss Vision, Cooper Vision, Essilor, and Alcon. Publisher Copyright: {\textcopyright} 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = apr,

day = "28",

doi = "10.1167/iovs.62.5.1",

language = "English",

volume = "62",

pages = "1--5",

journal = "Investigative ophthalmology & visual science",

issn = "0146-0404",

publisher = "Association for Research in Vision and Ophthalmology Inc.",

number = "5",

}

TY - JOUR

T1 - IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice

AU - Wolffsohn, James S

AU - Jong, Monica

AU - Smith, Earl L

AU - Resnikoff, Serge R

AU - Jonas, Jost B

AU - Logan, Nicola S

AU - Morgan, Ian

AU - Sankaridurg, Padmaja

AU - Ohno-Matsui, Kyoko

N1 - Funding Information: Supported by the International Myopia Institute. The publication costs of the International Myopia Institute reports were supported by donations from the Brien Holden Vision Institute, Carl Zeiss Vision, Cooper Vision, Essilor, and Alcon. Publisher Copyright: © 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/4/28

Y1 - 2021/4/28

N2 - The International Myopia Institute's (IMI) mission is to advance research, education, and management of myopia to decrease future vision impairment and blindness associated with increasing myopia. Its approach is to bring together scientists, clinicians, policymakers, government members, and educators into the field of myopia to stimulate collaboration and sharing of knowledge. The latest reports are on pathologic myopia, the impact of myopia, risk factors for myopia, accommodation and binocular vision in myopia development and progression, and the prevention of myopia and its progression. Together with the digest updating the 2019 International Myopia Institute white papers using the research published in the last 18 months, these evidence-based consensus white papers help to clarify the imperative for myopia control and the role of environmental modification initiatives, informing an evidence-based clinical approach. This guidance includes who to treat and when to start or stop treatment, and the advantages and limitations of different management approaches.

AB - The International Myopia Institute's (IMI) mission is to advance research, education, and management of myopia to decrease future vision impairment and blindness associated with increasing myopia. Its approach is to bring together scientists, clinicians, policymakers, government members, and educators into the field of myopia to stimulate collaboration and sharing of knowledge. The latest reports are on pathologic myopia, the impact of myopia, risk factors for myopia, accommodation and binocular vision in myopia development and progression, and the prevention of myopia and its progression. Together with the digest updating the 2019 International Myopia Institute white papers using the research published in the last 18 months, these evidence-based consensus white papers help to clarify the imperative for myopia control and the role of environmental modification initiatives, informing an evidence-based clinical approach. This guidance includes who to treat and when to start or stop treatment, and the advantages and limitations of different management approaches.

KW - Accommodation

KW - Myopia

KW - Myopia control

KW - Pathologic myopia

KW - Refractive error

UR - http://www.scopus.com/inward/record.url?scp=85104946811&partnerID=8YFLogxK

U2 - 10.1167/iovs.62.5.1

DO - 10.1167/iovs.62.5.1

M3 - Special issue

C2 - 33909037

SN - 0146-0404

VL - 62

SP - 1

EP - 5

JO - Investigative ophthalmology & visual science

JF - Investigative ophthalmology & visual science

IS - 5

M1 - 1

ER -

IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice

Abstract

Access to Document

Other files and links

Cite this